Next year is bringing many changes to the regulatory landscape for skilled nursing. With new payment rules, coding changes ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated ...

TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the ...

Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant ...

Inside Information: Accelerated approval pathway confirmed for frontline patients with CR + CReq, and Overall Survival as primary endpoints TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, ...

TURKU, FI / ACCESS Newswire / August 18, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel ...

Inside Information: Complete remission rate in frontline HR-MDS patients rose from 28% to 43% in latest data cut, confirming the deepening of responses over time. TURKU, FINLAND- Faron Pharmaceuticals ...

Median overall survival of 13.4 months in 32 r/r MDS patients treated with bexmarilimab + azacitidine ORR of 63% and 72% observed in patients with r/r MDS (n=32) and frontline MDS patients (n=18), ...

Please give an overview of 2L treatment strategies. If patients are refractory to the available 1L options, how would you choose a 2L treatment? Please give a brief overview of recent updates from ...

Panelists discuss how mutational burden impacts the response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), highlighting its role in predicting treatment outcomes and the ...